- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 27.05. | AROA BIOSURGERY LIMITED: Change in substantial holding | - | ASX | ||
| 26.05. | Biocurious: Aroa brings a touch of 'magic' to the US$3 billion woundcare sector | 1 | Stockhead | ||
| 26.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation - Correction | - | ASX | ||
| 26.05. | Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance | 2 | smallcaps.com.au | ||
| 25.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation | - | ASX | ||
| 25.05. | AROA BIOSURGERY LIMITED: FY26 Appendix 4E and Full Year Results | - | ASX | ||
| 18.05. | AROA BIOSURGERY LIMITED: Notification of Full Year Results Webinar | - | ASX | ||
| 30.04. | Health Check: Investors say "not baa-d" as Aroa smashes earnings expectations out of the paddock | 3 | Stockhead | ||
| 29.04. | AROA BIOSURGERY LIMITED: ARX FY26 Preliminary Results | - | ASX | ||
| 10.04. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 09.04. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | - | ASX | ||
| 30.03. | Aroa Biosurgery's Symphony Shows Positive Preliminary Results For Diabetic Foot Ulcers | 2 | RTTNews | ||
| 30.03. | AROA Biosurgery Completes Randomised Controlled Trial for Symphony; Preliminary Read-Out indicates Primary Endpoint Met | 327 | PR Newswire | AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony... ► Artikel lesen | |
| 29.03. | AROA BIOSURGERY LIMITED: Symphony Randomised Control Trial Complete | - | ASX | ||
| 24.03. | AROA BIOSURGERY LIMITED: Release of Shares from Voluntary Escrow | 1 | ASX | ||
| 10.03. | Vital Signs Podcast: Inside Aroa's MASTRR clinical registry | 1 | Stockhead | ||
| 03.02. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 03.02. | AROA BIOSURGERY LIMITED: Eligible NZ Employees Issued with ARX Shares | - | ASX | ||
| 02.02. | AROA BIOSURGERY LIMITED: AROA Business Update Presentation | - | ASX | ||
| 02.02. | AROA BIOSURGERY LIMITED: AROA Business Update | - | ASX |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | JEFFERIES stuft Biontech auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Biontech mit einem Kursziel von 138 US-Dollar auf "Buy" belassen. Die beiden Pharmakonzerne Pfizer und Biontech hätten auf der ASCO-Krebstagung... ► Artikel lesen | |
| EVOTEC | 4,932 | -3,58 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| MODERNA | 41,190 | +0,12 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| NOVAVAX | 8,080 | -1,70 % | NOVAVAX INC: Stabilität vor der nächsten Bewegung | ||
| HEIDELBERG PHARMA | 2,710 | +1,50 % | HEIDELBERG PHARMA AG: Ruhe vor der nächsten Phase | ||
| INOVIO PHARMACEUTICALS | 0,932 | +0,87 % | H.C. Wainwright senkt Kursziel für Inovio wegen höherer Aktienanzahl | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 49,500 | +0,49 % | BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders | Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing... ► Artikel lesen | |
| IBIO | 1,744 | +10,10 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,690 | +0,27 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| LAKEFRONT BIOTHERAPEUTICS | 24,400 | 0,00 % | Gilead Sciences, Inc.: Gilead Sciences and Lakefront Biotherapeutics Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline | - Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases -
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,580 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,242 | 0,00 % | Natera, CytoDyn Partner in Colorectal Cancer Study |
AROA BIOSURGERY LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.